ABBV
Abbvie Inc (ABBV)
Healthcare • NYSE • $201.55-0.57%
- Symbol
- ABBV
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Price
- $201.55
- Daily Change
- -0.57%
- Market Cap
- $356.49B
- Trailing P/E
- 98.80
- Forward P/E
- 12.43
- 52W High
- $244.81
- 52W Low
- $176.57
- Analyst Target
- $252.23
- Dividend Yield
- +3.43%
- Beta
- 0.30
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; …
Company websiteResearch ABBV on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.